CRISPR Therapeutics price to free cash flow CRSP

Market value divided by free cash flow over the last twelve months, since 2019.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 15.2×; Aug 2022
7-year median: 20.0×
7-year range: 8.1× to 220×
Peer median: 21.8×

CRISPR Therapeutics' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Aug 2022, at 15.2×.

On the days it had one over the last 7 years, its median was 20.0×, from 8.1× in May 2022 to 220× in Dec 2019.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2022	15.2×	8.1×	15.6×
2021	12.5×	11.5×	20.7×
2020	143×	45.8×	182×
2019	200×	153×	220×

Against its peers

Companies in Biotechnology nearest CRISPR Therapeutics' size, closest first, today.

Company	Price to free cash flow
CRSPCRISPR Therapeutics	n/m
KRYSKrystal Biotech	35.8×
ADMAAdma Biologics	20.5×
RGENRepligen	89.2×
VCELVericel	35.3×
TECHBIO-TECHNE	43.2×
HALOHalozyme Therapeutics	17.7×
NBIXNeurocrine Biosciences	16.7×
EXELExelixis	13.6×
INCYIncyte	12.2×
UTHRUnited Therapeutics	23.1×
Peer median	21.8×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on CRISPR Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.